PT1005332E - Composicao farmaceutica para reduzir a producao da proteina mcp-1 - Google Patents

Composicao farmaceutica para reduzir a producao da proteina mcp-1

Info

Publication number
PT1005332E
PT1005332E PT98943862T PT98943862T PT1005332E PT 1005332 E PT1005332 E PT 1005332E PT 98943862 T PT98943862 T PT 98943862T PT 98943862 T PT98943862 T PT 98943862T PT 1005332 E PT1005332 E PT 1005332E
Authority
PT
Portugal
Prior art keywords
reducing
production
pharmaceutical composition
protein mcp
mcp
Prior art date
Application number
PT98943862T
Other languages
English (en)
Portuguese (pt)
Inventor
Angelo Guglielmotti
Alberto Mantovani
Original Assignee
Aziende C R Angelini Francesco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende C R Angelini Francesco filed Critical Aziende C R Angelini Francesco
Publication of PT1005332E publication Critical patent/PT1005332E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT98943862T 1997-07-28 1998-07-22 Composicao farmaceutica para reduzir a producao da proteina mcp-1 PT1005332E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI001789A IT1293795B1 (it) 1997-07-28 1997-07-28 Farmaco attivo nel ridurre la produzione di proteina mcp-1

Publications (1)

Publication Number Publication Date
PT1005332E true PT1005332E (pt) 2004-03-31

Family

ID=11377642

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98943862T PT1005332E (pt) 1997-07-28 1998-07-22 Composicao farmaceutica para reduzir a producao da proteina mcp-1

Country Status (15)

Country Link
US (1) US6534534B1 (enExample)
EP (1) EP1005332B1 (enExample)
JP (2) JP4651191B2 (enExample)
AR (1) AR016382A1 (enExample)
AT (1) ATE251902T1 (enExample)
AU (1) AU744492B2 (enExample)
CA (1) CA2300289C (enExample)
DE (1) DE69819012T2 (enExample)
DK (1) DK1005332T3 (enExample)
ES (1) ES2207858T3 (enExample)
IT (1) IT1293795B1 (enExample)
PT (1) PT1005332E (enExample)
SI (1) SI1005332T1 (enExample)
WO (1) WO1999004770A2 (enExample)
ZA (1) ZA986636B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
ITMI20062254A1 (it) * 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
HRP20160457T1 (hr) 2008-03-07 2016-05-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1 i cx3cr1
US8835481B2 (en) * 2008-03-07 2014-09-16 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
CA2714436C (en) * 2008-03-07 2017-06-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
US8350052B2 (en) 2009-08-03 2013-01-08 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required magnesium intermediates
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US9250253B2 (en) 2010-02-25 2016-02-02 Prairie Ventures, L.L.C. System and method for anatomical pathology sample handling, storage, and analysis
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
ES2789849T3 (es) * 2014-05-15 2020-10-26 Translatum Medicus Inc Composiciones y procedimientos para el tratamiento y diagnóstico de trastornos oculares
EP3307068B1 (en) 2015-06-12 2021-08-25 Vettore, LLC Mct4 inhibitors for treating disease
ES2986065T3 (es) 2016-12-12 2024-11-08 Vettore Llc Inhibidores heterocíclicos de MCT4
EP3990433A4 (en) 2019-06-25 2023-07-26 Translatum Medicus Inc. METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
IT1253703B (it) 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
AU5537994A (en) * 1992-10-22 1994-05-09 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
JPH08333262A (ja) * 1995-04-07 1996-12-17 Chugai Pharmaceut Co Ltd 免疫抑制剤
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19538402A1 (de) * 1995-10-14 1997-04-17 Boehringer Mannheim Gmbh Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel
JPH09165339A (ja) * 1995-10-27 1997-06-24 American Home Prod Corp ラパマイシンを付与したドナー脾細胞を用いる臓器移植の延長
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1

Also Published As

Publication number Publication date
DK1005332T3 (da) 2004-02-09
WO1999004770A2 (en) 1999-02-04
EP1005332B1 (en) 2003-10-15
AU9160198A (en) 1999-02-16
DE69819012T2 (de) 2004-08-12
ATE251902T1 (de) 2003-11-15
EP1005332A2 (en) 2000-06-07
AU744492B2 (en) 2002-02-28
AR016382A1 (es) 2001-07-04
US6534534B1 (en) 2003-03-18
ES2207858T3 (es) 2004-06-01
DE69819012D1 (de) 2003-11-20
IT1293795B1 (it) 1999-03-10
SI1005332T1 (en) 2004-02-29
HK1028561A1 (en) 2001-02-23
JP4651191B2 (ja) 2011-03-16
CA2300289C (en) 2007-11-20
JP5086322B2 (ja) 2012-11-28
JP2010047609A (ja) 2010-03-04
WO1999004770A3 (en) 1999-04-15
ITMI971789A1 (it) 1999-01-28
ZA986636B (en) 1999-02-04
JP2001510793A (ja) 2001-08-07
CA2300289A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
IS4974A (is) Lyfjasamsetning á þrýstingsúðaformi
FI955311A0 (fi) Farmaseuttinen koostumuspohja
NO962606L (no) Farmasöytisk sammensetning
ID24654A (id) Formulasi farmasi omeprazola
PT1005332E (pt) Composicao farmaceutica para reduzir a producao da proteina mcp-1
ID26137A (id) Komposisi farmasi baru dari uridin trifosfat
EE9900545A (et) Farmatseutiline kompositsioon
BR9507768A (pt) Composição farmacêutica
ID29294A (id) Komposisi farmasi
FI973229A7 (fi) Uusi farmaseuttinen koostumus
LV11727A (lv) Farmaceitiska kompozicija
ID25857A (id) Komposisi farmasi
FI973280A0 (fi) Farmaseuttinen koostumus
ID26215A (id) Komposisi farmasi
BR9605777A (pt) Composição farmacêutica
PT1171470E (pt) Anticorpos para a proteina placentaria 13
ID23531A (id) Komposisi farmasi
BR9605131A (pt) Composição farmacêutica
SE9402924D0 (sv) Novel pharmaceutical composition
BR1100755A (pt) composição farmacêutica
SE9402437D0 (sv) Pharmaceutical composition
KR960016881A (ko) 제약 조성물
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste